Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92942Research ArticleRozuvastatin: novye tseli lecheniya bol'nogo iz gruppy riska sosudistykh oslozhneniy aterosklerozaZateyshchikovD. A-15052009115889128122021Copyright © 2009, Consilium Medicum2009[Parka J-K, Mervaala E.M.A., Muller D.N. et al. Rosuvastatin protects against angiotensin II - induced renal injury in a dose - dependent fashion. J Hypertens 2009; 27: 599–605.][Cormack-Aboud F.C., Brinkkoetter P.T., Pippin J.W. et al. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 2009; 24: 404–12.][Rosuvastatin Increases Extracellular Adenosine Formation in Humans in vivo. A New Perspective on Cardiovascular Protection. P.Meijer, W.J.G.Oyen, D.Dekker et al. Arterioscler. Thromb Vasc Biol 2009; 29: 963–8.][Jialal I, Devaraj S, Venugopal S. C-Reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44 (1): 6–11.][Ridker P.M., Rifai N, Pfeffer A et al. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Circulation 1998; 98: 839–44.][Mannacio V.A., Iorio D, De Amicis V et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial. J Thorac Cardiovasc Surg 2008; 136: 1541–8.][Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13 (3): 123–9.][The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High - dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.][Bonetti P.O., Lerman L.O., Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24: 225–48.][Heeschen С, Hamm C.W., Laufs U et al. Withdrawal of statins increases event rats in patients with acute coronary syndromes. Circulation 2002; 105: 1446–52.][Glynn R.J., Danielson E, Fonseca F.A.H. et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360: 1851–61.][Ridker P.M., Danielson E, Fonseca F.A. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373 (9670): 1175–82.][Michos E.D., Blumenthal R.S. Prevalence of Low Low - Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of theJUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009; 53: 931–5.]